Consequently, a number of Lp‐PLA2 inhibitors were discovered, among which, darapladib (developed by GSK) is the most advanced and most widely studied Lp‐PLA2 inhibitor.154 As a potent oral inhibitor of Lp‐PLA2, darapladib was used as a candidate drug to elucidate the influence of Lp‐PLA2 inhibition on a range of cardiovascular and CVDs, including stroke, myocardial ischemia, subclinical atherosclerosis, CHD, and heart failure.155, 156 Recently, Campos et al157 extensively summarized the major preclinical and clinical studies on darapladib for atherosclerosis. This evidence concerns the gene PLA2G7 and heart failure.